S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Copper Exploration Heating Up (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Copper Exploration Heating Up (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Copper Exploration Heating Up (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Copper Exploration Heating Up (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:PGEN

Precigen - PGEN Stock Forecast, Price & News

$1.82
0.00 (0.00%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.77
$1.85
50-Day Range
$1.47
$2.02
52-Week Range
$1.12
$4.19
Volume
837,215 shs
Average Volume
847,878 shs
Market Capitalization
$378.83 million
P/E Ratio
15.17
Dividend Yield
N/A
Price Target
$9.00

Precigen MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
394.5% Upside
$9.00 Price Target
Short Interest
Bearish
7.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

137th out of 1,052 stocks

Pharmaceutical Preparations Industry

54th out of 514 stocks

PGEN stock logo

About Precigen (NASDAQ:PGEN) Stock

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Receive PGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter.

PGEN Stock News Headlines

Precigen (NASDAQ:PGEN) Coverage Initiated at Cantor Fitzgerald
Precigen Names Rutul R. Shah Chief Operating Officer
Precigen, Inc. (NASDAQ: PGEN)
Form 8-K PRECIGEN, INC. For: Aug 18 - StreetInsider.com
See More Headlines
Receive PGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter.

PGEN Company Calendar

Last Earnings
11/08/2021
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PGEN
Fax
N/A
Employees
456
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+394.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-92,170,000.00
Pretax Margin
-93.31%

Debt

Sales & Book Value

Annual Sales
$103.87 million
Book Value
$0.68 per share

Miscellaneous

Free Float
117,188,000
Market Cap
$378.83 million
Optionable
Optionable
Beta
1.88

Key Executives

  • Mr. Randal J. Kirk J.D.Mr. Randal J. Kirk J.D. (Age 69)
    Exec. Chairman
    Comp: $100k
  • Dr. Helen Sabzevari MPH (Age 60)
    Ph.D., Pres, CEO & Director
    Comp: $1.77M
  • Mr. Harry Thomasian Jr.Mr. Harry Thomasian Jr. (Age 60)
    Chief Financial Officer
    Comp: $470.97k
  • Mr. Donald P. Lehr (Age 47)
    Chief Legal Officer & Corp. Sec.
    Comp: $690.76k
  • Mr. Jeffrey Thomas PerezMr. Jeffrey Thomas Perez (Age 50)
    Sr. VP of Intellectual Property Affairs
    Comp: $603.54k
  • Dr. Thomas D. Reed (Age 56)
    Founder & Chief Science Officer
  • Mr. Rutul R. Shah
    Chief Operating Officer
  • Mr. Steven Harasym
    VP & Head of Investor Relations
  • Marie Rossi
    VP of Communications
  • Mr. Rob Russell
    VP & Head of HR













PGEN Stock - Frequently Asked Questions

Should I buy or sell Precigen stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PGEN shares.
View PGEN analyst ratings
or view top-rated stocks.

What is Precigen's stock price forecast for 2023?

3 brokers have issued 12 month price targets for Precigen's stock. Their PGEN share price forecasts range from $6.00 to $14.00. On average, they predict the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 394.5% from the stock's current price.
View analysts price targets for PGEN
or view top-rated stocks among Wall Street analysts.

How have PGEN shares performed in 2022?

Precigen's stock was trading at $3.71 at the beginning of the year. Since then, PGEN shares have decreased by 50.9% and is now trading at $1.82.
View the best growth stocks for 2022 here
.

When is Precigen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our PGEN earnings forecast
.

How were Precigen's earnings last quarter?

Precigen, Inc. (NASDAQ:PGEN) issued its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01. The biotechnology company had revenue of $21.56 million for the quarter, compared to analysts' expectations of $24.47 million. Precigen had a net margin of 33.55% and a negative trailing twelve-month return on equity of 82.23%.

What other stocks do shareholders of Precigen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), NVIDIA (NVDA) and Bausch Health Companies (BHC).

What is Precigen's stock symbol?

Precigen trades on the NASDAQ under the ticker symbol "PGEN."

Who are Precigen's major shareholders?

Precigen's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.76%), Vanguard Group Inc. (2.44%), Iridian Asset Management LLC CT (1.54%), State Street Corp (0.93%), Renaissance Technologies LLC (0.40%) and Nuveen Asset Management LLC (0.29%). Insiders that own company stock include David M Obstler, Donald P Lehr, Harry Jr Thomasian, Helen Sabzevari, Jeffrey B Kindler, Jeffrey Thomas Perez, Jennifer I Ansberry, John N Digiacomo, Randal J Kirk, Rick L Sterling, Thomas Bostick and Trading SA Ares.
View institutional ownership trends
.

How do I buy shares of Precigen?

Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precigen's stock price today?

One share of PGEN stock can currently be purchased for approximately $1.82.

How much money does Precigen make?

Precigen (NASDAQ:PGEN) has a market capitalization of $378.83 million and generates $103.87 million in revenue each year. The biotechnology company earns $-92,170,000.00 in net income (profit) each year or $0.12 on an earnings per share basis.

How many employees does Precigen have?

The company employs 456 workers across the globe.

How can I contact Precigen?

Precigen's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The official website for the company is www.precigen.com. The biotechnology company can be reached via phone at (301) 556-9900 or via email at investors@precigen.com.

This page (NASDAQ:PGEN) was last updated on 12/2/2022 by MarketBeat.com Staff